Ryan Livingston

A recent secondary analysis of the HELIOS-B trial has highlighted vutrisiran’s effects on atrial myopathy in patients with ATTR-CM.

The phase 3 trial showed a 55% reduction in Level 2 and Level 3 hypoglycemic events versus placebo, meeting all secondary endpoints.

The FDA approved a single-use autoinjector for lerodalcibep-liga alongside an updated lerodalcibep-liga indication reflecting MACE risk reduction from LDL-C lowering with statins or add-on PCSK9 inhibitors.

Novo Nordisk's once-weekly insulin icodec-abae (Awiqli) has launched nationwide for adults with type 2 diabetes.

Get ahead of the curve with the top 6 trials to watch ahead of ESC 2026.

Phase 3 LEVEL trial of TNX-103 missed its primary 6MWD endpoint in PH-HFpEF, though a sicker patient subgroup showed benefit versus placebo.

In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.

Examining individual pregnancy outcomes rather than defining women by the presence or absence of complications more reliably predicts later CVD death.

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.

All cardiovascular disease risks decreased proportionately across all quintiles of diet consistency, according to recent data.

The ACC's new decision pathway incorporates SGLT2 inhibitor finerenone and data on incretin therapy into HFpEF diagnosis and management guidance.

CaRi-Heart measures coronary inflammation from routine CT angiography and generates a personalized 10-year cardiovascular mortality risk score.

The FDA has officially granted Fast Track designation to HTX-001 for the treatment of non-obstructive hypertrophic cardiomyopathy.

The Voluntary Sodium Reduction Goals, issued in October 2021, resulted in no significant reduction in sodium content among packaged foods.

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

According to a recent study, nearly 32.2% of US adults are well above their LDL-C targets to avoid atherosclerotic cardiovascular disease.

After broadening eligibility criteria across several disease states and a wider age range, the new guidelines have made an estimated 87.5 million adults eligible for statins.

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.

A recent analysis of data from the Global Burden of Disease Study has indicated a relationship between risk of death from ACHD and socioeconomic factors.

FDA approved once-daily oral enlicitide to lower LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

These modifiable factors, among others, directly contribute to 88.7% of all IHD deaths in 2023.

New data from the 45-patient Midpoint Cohort, despite not being powered for statistical significance, indicate a potentially substantial benefit.

Eplontersen did not significantly reduce cardiovascular mortality and recurrent cardiovascular events in the phase 3 CARDIO-TTRansform trial.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.